Raab Stephen S, Grzybicki Dana Marie, Hart Alison R, Kiely Sharon, Andrew-JaJa Carey, Scioscia Eugene
Department of Pathology and Laboratory Medicine, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Am J Clin Pathol. 2002 Apr;117(4):524-33. doi: 10.1309/XNUG-XH8V-C1KM-T6GD.
The amount of money a woman is willing to pay for liquid-based cytology technology has not been measured. In the present study, 175 women answered a questionnaire asking how much they would pay to decrease their risk of dying of cervical cancer if a new (liquid-based) Papanicolaou (Pap) test was used in place of the conventional smear. When women assumed that the new Pap test reduced the risk of dying of cervical cancer from 1 in 37,000 to 1 in 50,000, the mean amount they were willing to pay was $237. If women had more than 2 children, they were willing to pay more for the new Pap test than women with 2 or fewer children. These data indicate that liquid-based and conventional Pap tests are undervalued and that cost-effectiveness studies generally have not taken into account the preference of women for new Pap test technologies.
女性愿意为液基细胞学技术支付的费用尚未得到衡量。在本研究中，175名女性回答了一份问卷，询问如果使用新的（液基）巴氏涂片检查代替传统涂片检查，她们愿意支付多少钱来降低死于宫颈癌的风险。当女性认为新的巴氏涂片检查将死于宫颈癌的风险从37000分之一降低到50000分之一时，她们愿意支付的平均金额为237美元。如果女性生育的孩子超过2个，她们比生育2个或更少孩子的女性更愿意为新的巴氏涂片检查支付更多费用。这些数据表明，液基和传统巴氏涂片检查的价值被低估，而且成本效益研究通常没有考虑到女性对新巴氏涂片检查技术的偏好。
